



Altimune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022

May 20, 2022

GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company's novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris will also moderate a panel discussion on clinical endpoints in NASH trials.

Details for the oral presentation are as follows:

Title:	The Emerging Weight Loss Therapeutics and Implications for the NASH Treatment Paradigm
Presenter:	Scott Harris, M.D., Chief Medical Officer, Altimune, Inc.
Date/Time:	Friday, May 27, 2022 at 3:15 pm BST

A copy of Dr. Harris' presentation will be accessible on the [Events](#) section of the Altimune website.

Details for the panel discussion are as follows:

Title:	Clinical Endpoints for NASH Trials
Moderator:	Scott Harris, M.D., Chief Medical Officer, Altimune, Inc.
Date/Time:	Friday, May 27, 2022 at 9:35 am BST

About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

Investor & Media Contacts:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com



Source: Altimune, Inc